Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10954-1
A specific population of macrophages that express high levels of the enzyme PLA2G2D in tumour-draining lymph nodes is associated with poor prognosis in patients, and inhibiting PLA2G2D improves anti-tumour immunity in mouse models.
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10979-6
An imaging system developed to record cellular activity throughout the whole body of zebrafish captures cellular organ dynamics and identifies multiple distributed circuits.
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10998-3
TRI-611 induces the degradation of ALK fusion proteins via a previously undescribed CRBN recruitment motif, and its preclinical anti-tumour activity highlights TRI-611 as a potential new way of treating ALK-positive non-small-cell lung cancer.
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10468-w
Eight integrated mutational footprints collectively explain the mutational processes in 85% of primary prostate cancer genomes.
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10993-8
TM184C—an ancient G-protein-coupled receptor-like superdark protein involved in regulation of autophagy, intercellular connectivity and material exchange—underscores the promise of exploring the understudied human proteome and beyond.
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04647-5
Consensus framework for the validation of generative AI: call for collaborators on the Validation Accords
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04607-z
Following preclinical development, a randomized first-in-human trial showed that treatment with an inhaled, lung-epithelium-targeted siRNA directed against the receptor for advanced glycation end-products (RAGE) was safe and well tolerated and reduced RAGE levels in serum and bronchoalveolar lavage fluid.
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04615-z
In a phase 2 randomized clinical trial, treatment with the myeloperoxidase (MPO) inhibitor mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.
npj Digital Medicine, Published online: 09 September 2026; doi:10.1038/s41746-026-03197-x
A global framework for artificial intelligence education in medicine: international working group recommendations
Nature, Published online: 08 September 2026; doi:10.1038/d41586-026-02795-9
Limit bets on clinical-trial outcomes being placed on prediction markets
Nature Biotechnology, Published online: 07 September 2026; doi:10.1038/s41587-026-03286-y
Six proteomic clocks are applied in a clinical trial to assess anti-aging effects.
Oncogene, Published online: 04 September 2026; doi:10.1038/s41388-026-03964-w
A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK–RAS mutations
Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01243-x
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
Oncogene, Published online: 01 September 2026; doi:10.1038/s41388-026-03969-5
Neuromedin U ‘innervation’ reprograms myeloid immunosuppression in neuroendocrine prostate cancer
Nature Cancer, Published online: 31 August 2026; doi:10.1038/s43018-026-01225-z
In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal adenocarcinoma and determine the recommended phase 2 dose of l-glutamine in combination with gemcitabine and nab-paclitaxel.
Login